Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Humanin structure

Humanin

Other
Phase 1 Research
30%
Low-Moderate Risk
2/5

Dosing Protocol

Typical Dose 2 mg
Range 1 - 4 mg
Maintenance 2 mg daily

Pharmacokinetics

Half-Life 30 min
Onset 10 min
Peak 30 min
Duration 2.0 hrs
Bioavailability 85%
Primary Route Subcutaneous

Administration

Routes Subcutaneous, Intravenous
Injection Sites Abdomen, Thigh
Needle Gauge 29-31G
Syringe Type Insulin
Timing Morning

Reconstitution

Diluent Bacteriostatic Water
Volume 1 mL
Stability 7 days refrigerated
Vial Sizes 5 mg

Special Instructions

Short half-life in vivo. Synthetic analogs (HNG, Colivelin) have improved stability. Research compound.